Goldman Sachs analyst Corinne Johnson resumed coverage of ArriVent Biopharma (AVBP) with a Buy rating and $33 price target The firm sees a high probability that the Phase3 FURVENT results demonstrate competitive clinical efficacy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVBP:
- ArriVent BioPharma Announces $75 Million Public Offering
- ArriVent Biopharma 2.5M share Spot Secondary priced at $19.50
- ArriVent Biopharma announces $75M common stock, warrants offering
- ArriVent Biopharma initiated with a Buy at Clear Street
- ArriVent Biopharma price target raised to $44 from $39 at Oppenheimer